Pet Cancer Therapeutics Market Top Players: Zoetis, Merial, Aratana Therapeutics, AB Science, Vetivax, Oasmia Pharmaceutical, VetDC, Regeneus, CanFel Therapeutics
Pet Cancer Therapeutics Market valued above USD 140 million in 2016 and is projected to witness more than 10% CAGR from 2017 to 2024.
Sellbyville, DE -- (SBWire) -- 12/07/2018 --Pet Cancer Therapeutics Market size to exceed USD 300 million by 2024, as per a new research report by Global Market Insights, Inc.
Growing pet adoption rate coupled with increasing disposable income of pet owners will drive pet cancer therapeutics market growth. Strong and robust drug pipeline for treatment of pet cancer will stimulate business growth over the forecast years.
High cost of pet cancer drugs along with rising instances of adverse drug events should hamper industry growth over the forecast years. Lack of awareness regarding pet diseases among the pet owners will impede industry expansion.
Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/2017
Chemotherapy has been the mainstream medication for pet cancers till recent times. However, immunological vaccines entered the market and are gaining significant market share. With number of chemotherapy drugs in pipeline, the industry should witness considerable growth over the coming years.
Dogs are more prone to develop cancer than cats and the healthy pipeline will drive segment growth over the forecast years. However, introduction of specialized cat cancer medicines will stimulate the cat cancer therapeutics market growth.
Pet healthcare companies are focusing on development of drugs for mast cell cancer and melanoma among other cancer types. This trend will witness change as medicines to treat lymphoma and mammary cell cancer are in the pipeline. Innovative medicines for treatment of multiple cancer tumors is anticipated to accelerate business growth.
Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/2017
U.S. pet cancer therapeutics market holds the largest revenue share in 2016. Presence of large number of pet drug manufacturing companies, quick adoption of innovative pet care medicines and increasing disposable income of pet owners will boost industry growth.
Australia pet cancer therapeutics market held highest regional revenue share in 2016 owing to growing pet-keeping trend, availability of innovative pet care medicines and increasing disposable income of pet owners.
Some of the leading industry players include Zoetis, Merial, Aratana Therapeutics, AB Science, Vetivax, Oasmia Pharmaceutical, VetDC, Regeneus, CanFel Therapeutics, Karyopharms Verdinexor. The most commonly adopted business strategies by industry participants includes new product launches, regional expansion and mergers and acquisition.
Chapter 1. Methodology
1.1.1. Initial data exploration
1.1.2. Statistical model and forecast
1.1.3. Industry insights and validation
1.1.4. Market definition & forecast parameters
1.2. Data sources
Chapter 2. Executive Summary
2.1. Pet cancer therapeutics market 3600 synopsis, 2013 –2024
2.1.1. Business trends
2.1.2. Medicine type trends
2.1.3. Species trends
2.1.4. Cancer type trends
2.1.5. Regional trends
Chapter 3. Pet cancer therapeutics Industry Insights
3.1. Industry segmentation
3.2. Industry size and forecast, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
188.8.131.52. Rising number of pets' population
184.108.40.206. Increasing prevalence of cancer in pets
220.127.116.11. Rising willingness of pet owners to spend on pet healthcare
18.104.22.168. Increasing number of new product development
3.3.2. Industry pitfalls & challenges
22.214.171.124. Side-effects of Pet cancer therapeutics
126.96.36.199. Dearth of veterinary oncologist
188.8.131.52. Low out of pocket expenditure on pet healthcare in developing countries
3.4. Regulatory landscape
3.5. Technology landscape
3.5.1. North America
3.6. Pipeline analysis
3.7. Growth potential analysis
3.8. Porter's analysis
3.9. Competitive landscape, 2016
3.10. PESTEL analysis
Media Relations Contact
View this press release online at: http://rwire.com/1098502